

# **KELLY PENDERGRASS, M.D.**

## **CURRICULUM VITAE**

Kansas City Cancer Center  
1000 E. 101<sup>st</sup> Terrace  
Kansas City, Missouri 64131

## **PROFESSIONAL DESIGNATION**

### ***Licensed to Practice Medicine:***

Kansas  
Missouri

### ***Board Certifications:***

American Board of Internal Medicine—Diplomate in Oncology 1981  
American Board of Internal Medicine—Diplomate 1980

## **EDUCATIONAL BACKGROUND**

Johns Hopkins Hospital *Baltimore, MD*  
**Medical Oncology Fellowship** 1979

Brown University, Roger Williams General Hospital *Providence, RI*  
**Oncology/Hematology Fellowship** 1978

Baptist Memorial Hospital, University of Tennessee *Memphis, TN*  
**Internal Medicine Internship/Residency** 1978

University of Kansas School of Medicine *Kansas City, KS*  
**Doctorate of Medicine** 1975

University of Kansas *Lawrence, KS*  
**Bachelor of Arts—History** 1971

**KELLY PENDERGRASS, M.D.**  
**CURRICULUM VITAE—PAGE 2**  
**PROFESSIONAL EXPERIENCE**

Kansas City Cancer Centers	2000-Present
Kansas City Internal Medicine, M.D's	1980-2000

**PROFESSIONAL APPOINTMENTS**

University of Missouri School of Medicine; Kansas City, MO <b>Clinical Professor</b>	1999-Present
Research Medical Center; Kansas City, MO <b>Multidisciplinary Oncology Conference Chair</b>	1981-2001
Research Medical Center; Kansas City, MO <b>Section of Oncology Professor and Chief</b>	1980-2001
Research Medical Center; Kansas City, MO <b>Oncology Unit Director</b>	1980-2001
Research Medical Center; Kansas City, MO <b>Cancer Commission Chair, American College of Physicians</b>	1981-2000
University of Missouri School of Medicine; Kansas City, MO <b>Clinical Associate Professor</b>	1987-1999
Johns Hopkins Hospital <b>Active Staff</b>	1979-1980
Johns Hopkins Hospital University School of Medicine; Baltimore, MD <b>Assistant in Oncology—Fellow</b>	1979-1980
Brown University; Providence, RI <b>Assistant in Internal Medicine</b>	1978-1979

**PROFESSIONAL AND BOARD AFFILIATIONS**

Kansas City Leukemia Society <b>Executive Board</b>	1982-1985, 2002-Present
University of Nebraska Lymphoma Study Group	1990-Present
Heart of America Bone Marrow Registry <b>Medical Director</b>	1988-Present

National Marrow Donor Program	1988-Present
Heart of America Bone Marrow Registry <b>Medical Advisory Board</b>	1985-Present
Kansas City Round Table of Oncology <b>Executive Board</b>	1982-Present
Donor and Collections Centers—NMDP <b>Medical Director</b>	Present
Aventis <b>Speakers Bureau</b>	Present
Immunex <b>Speakers Bureau</b>	Present
Glaxo, Inc. <b>Speakers Bureau</b>	Present
Novartis <b>Speakers Bureau</b>	Present
Astra Zeneca <b>Speakers Bureau</b>	Present
Berlex <b>Speakers Bureau</b>	Present
Cell Therapeutics <b>Speakers Bureau</b>	Present
Research Medical Center <b>Multi-Disciplinary Oncology Conference Chair</b>	1981-2001
Research Medical Center <b>Executive Committee</b>	1981-2001
Research Medical Center <b>Cancer Commission Chair</b>	1982-2000
The Missouri Society of Clinical Oncology <b>Vice President</b>	1996-1998

Hospital Medical Staff Section of the AMA <b>Representative</b>	1985-1990
The Bixby Cancer Symposium <b>Chair</b>	1989
The Leukemia Society—Mid America Chapter <b>Vice President</b>	1988
Research Medical Center <b>Investigative Review Board</b>	1982-1988
The Bixby Cancer Symposium <b>Chair</b>	1985
American Cancer Society—Kansas City, Executive Committee <b>Medical Advisory Board</b>	1984
Kansas City Clinical Oncology Program Breast Committee <b>Chair</b>	1983
The Southwest Clinical Society Executive Committee	1981-1983
Kansas City Southwest Clinical Society <b>Chair</b>	1982

### HOSPITAL AFFILIATIONS

Baptist Medical Center	Kansas City, MO	1998-present
Research Medical Center	Kansas City, MO	1980-present

### PRESENTATIONS

"Efficacy and Safety of 100 mg Oral Ondansetron Mesylate Plus 20 mg Oral Dexamethasone in Level 5 Chemotherapy." Grote, T., **Pendergrass, K.**, et al. Supportive Care in Cancer, MASCC International Symposium, Nice, France, 1999. Abstract.

"A Selective Neurokinin-1 Antagonist, Reduces Cisplatin-induced Acute and Delayed Emesis: A double blind, Randomized Trial." Gertz, B. J., Gralla, R. J., Grote, T. H., Hesketh, P., Khojasteh, A., Kindler, H., Kris, M. G., Navari, R.,

**Pendergrass, K.**, Reinhardt, R. R., Program/Proceedings, American Society of Clinical Oncology, 1998.

"Double-blind, Randomized, Study of the Dose-response Relationship Across Five Single Doses of IV Dolasetron Mesylate (DM) for Prevention of Acute Nausea and Vomiting (ANC) after Cisplatin Chemotherapy (CCT)." **Pendergrass, K.**, Thant, M., et al. 6th International Congress on Anti-Cancer Treatment, Paris, France, 1996. Abstract.

"Pooled Dose Response Analysis Across Eight Clinical Trials assessing the Acute Antiemetic Efficacy of IV Dolasetron Mesylate (DM) after Emetogenic Chemotherapy (CT)." **Pendergrass, K.**, Thant, M., et al. 6th International Congress on Anti-Cancer Treatment, Paris, France, 1996. Abstract.

"Double-blind, Randomized, Dose-response Study of the Antiemetic Effect of Five Single Doses of Intravenous (IV) Dolasetron Mesylate (DM) in Patients Receiving Cisplatin Chemotherapy (CT)." **Pendergrass, K. B.**, Thant, M., et al. 6th International Congress on Anti-Cancer Treatment, Paris, France, 1996. Abstract.

"A Double-Blind, Stratified, Randomized Comparison of Intravenous (IV) Ondansetron Administered as a Multiple Dose Regimen Versus Two Single Dose Regimens in the Prevention of Cisplatin-Induced Nausea and Vomiting." Beck, T. M., Bryson, J. C., House, K. W., Lester, E. P., Madajewicz, S., Navari, R. M., **Pendergrass, K.** #1311. Program/Proceedings, American Society of Clinical Oncology Annual Meeting, San Diego, CA, May 1992.

"Dexrazoxane, (ADR-529, ICRF-187, Zinecard) Protects Against Doxorubicin Induced Chronic Cardiotoxicity." Abramson, N., Banks, P. L. C., Bianchine, J., Curtis, N., Desai, A. M., Feldman, J. E., Filppi, J., Gams, R. A., Hennebert, B., Hess, D. L., Imondi, A., Jones, D., Jones, S. E., Joseph, R. R., Khojasteh, A., Kline, A., Lusch, C. J., Lyman, G. H., Mittleman, A., Moore, J. O., Narang, P. K., Palepu, N., **Pendergrass, K. B.**, Reynolds, R. D., Rosenfeld, C. S., Scott, D., Spicer, D. V., Squillace, K., Swain, S. M., Trantum, B. L., Velez-Garcia, E., Verhoef, V., Vogel, C. L., Wadler, S., Weisberg, S. R., Winston, J., York, R. M. Adria Laboratories Cooperative Study, #190. Program/Proceedings, American Society of Clinical Oncology Annual Meeting, San Diego, CA, May 1992. Abstract.

"Advanced Small Cell Lung Cancer Treated with CAV (Cyclophosphamide + Adriamycin + Vincristine) Chemotherapy and the Cardioprotective Agent Dexrazoxane (ADR-529, ICRF-187 Zinecard)." Abramson, N., Banks, P., Feldman, J. E., Gams, R. A., Gandara, D. R., Gerber, M., Hayes, D. M., Hess, D., Horvath, W. L., Jones, D., Jones, G., Jones, S. E., Khojasteh, A., Kline, A., Lyman, G. H., Mailliard, J. A., **Pendergrass, K. B.**, Reynolds, R. D., Rivera, R. R., Scott, D., Shaikh, B. S., Spaulding, M. B., Squillace, K., Swearingin, B., Trantum, B., Wajima, T., Weisberg, S. R., Winston, J., York, R. M. Adria Laboratories Cooperative Study, #993. Program/Proceedings, American Society of Clinical Oncology Annual Meeting, San Diego, CA, May 1992. Abstract.

"Radionuclide Resting Left Ventricular Ejection Fraction (LVEF/MUGA) Measurements in Breast Cancer Patients Receiving Adriamycin Based Chemotherapy for Advanced Disease." Abramson, N., Banks, P., Desai, A. M., Feldman, J. E., Gams, R. A., Jones, S. E., Joseph, R. R., Khojasteh, A., Lusch, C. J., Lyman, G. H., Mailliard, J., Mittleman, A., Moore, J. O., **Pendergrass, K. B.**, Reynolds, R. D., Rosenfeld, C. S., Spicer, D. V., Swain, S. M., Trantum, B. L., Velez-Garcia, E., Vogel, C. L., Wadler, S., Weisberg, S. R., York, R. M. #192. Program/Proceedings, American Society of Clinical Oncology Annual Meeting, San Diego, CA, May 1992.

"Prevention of Adriamycin Cardiomyopathy with Dexrazoxane (ADR-529, ICRF-187)." Abramson, N., Banks, P. L. C., Bianchine, J., Curtis, N., Desai, A. M., Feldmann, J. E., Gams, R. A., Hess, D. L., Jones, D., Jones, S.E., Joseph, R. R., Khojasteh, A., Kline, A., Lusch, C. J., Lyman, G. H., Mittleman, A., Moore, J. O., Narang, P. K., **Pendergrass, K. B.**, Reynolds, R. D., Rosenfeld, C. S., Scott, D., Spicer, D. V., Squillace, K., Swain, S. M., Trantum, B. L., Velez-Garcia, E., Vogel, C. L., Wadler, S., Weisberg, S. R., Winston, J., York, R. M. #74. Program/Proceedings, American Society of Clinical Oncology Annual Meeting, San Diego, CA, 1992.

"Cisplatin/Carboplatin." Participant/Moderator. Bristol Symposium, Maui, Hawaii, Program/Proceedings, American Society of Clinical Oncology Meeting, Orlando, FL, September, 1990.

"Ondansetron: More Effective Than Metoclopramide in the Prevention of Cisplatin Induced Nausea and Vomiting." #1234. Program/Proceedings, American Society of Clinical Oncology Annual Meeting, Washington, D. C., May, 1990.

"Intensive Timed Sequential Combination Chemotherapy and Adjunctive Radiotherapy in Extensive Stage Cell Carcinoma of the Lung."

Program/Proceedings, American Society of Clinical Oncology Annual Meeting, San Diego, May 1980. Abstract.

### PUBLICATIONS AND ABSTRACTS

"Cancer of Unknown Primary Sites." Myers, J. S., **Pendergrass, K. B.** Oncology Nursing Secrets, 2nd Edition, Rose A. Gates & Regina M. Fink (Eds.), Philadelphia, PA. Handley & Belfus, Inc., 2001.

"Options in the Treatment of Chemotherapy-Induced Emesis." **Pendergrass, K.**, Cancer Practice, 6:1065-4074, 1998.

"Oral Dolasetron Mesylate in Patients Receiving Moderately Emetogenic Platinum-containing Chemotherapy." Benedict, C. R., Figlin, R. A., Grote, T., Hahne, W. F., Hesketh, P. J., Karlan, B. Y., Reeves, J. A., **Pendergrass, K. B.**, Pineda, L. F., Poerter, L. L. The Cancer Journal from Scientific American, 3:45-51, 1997.

"Double-blind, Randomized, Dose-response Study of Intravenous Dolasetron Mesylate For Prevention of Acute Nausea and Vomiting in Patients Receiving High-dose Cisplatin Chemotherapy." Benedict, C., Edelman, M., Gandara, D., Harman, G., Modiano, M., **Pendergrass, K.**, Sridhar, K., Thanos, M. Journal Clinical Oncology, 1997.

"High-Dose Chemotherapy and Peripheral Blood Stem Cell Infusion in Patients with non-Hodgkin's Lymphoma: Results of Outpatient Treatment in Community Cancer Centers." Buckner, C. D., Greco, F. A., Hainsworth, J., Kaywin, P., Leff, R., Mangum, M., **Pendergrass K.**, Rosenberg, A., Schwartzberg, B., Tauer, K., Weaver, C. H., West, W. H., Zhen, B. Clinical Research Division of Response Oncology, Inc., Memphis, TN. Bone Marrow Transplantation, 20:753-760, 1997.

"Prevention of Acute Emesis in Cancer Patients Following High-Dose Cisplatin with the Combination of Oral Dolasetron and Dexamethasone." Kris, M. D., Navari, R. M., **Pendergrass, K. B.**, et al. Journal Clinical Oncology, 15:2135-2138, 1997.

"Analysis of Optimal Dose From Eight Pooled Clinical Trials Assessing the Acute Antiemetic Efficacy of IV Dolasetron Mesylate After Emetogenic Chemotherapy." Audhu, B., Hesketh, P., **Pendergrass, K.**, et al. Proceedings, American Society Clinical Oncology, 15:547, 1996. Abstract.

"Selecting the Optimal Dolasetron Dose for Antiemesis after Emetogenic Chemotherapy (ECT): A Pooled Analysis." Audhuy B., **Pendergrass, K. B.**, et al. Annals of Oncology, 7:139, 1996.

"Oral Dolasetron Plus Dexamethasone Delays Time to Emesis More Effectively Than IV Ondansetron or IV Dolasetron Alone in High-Dose Cisplatin." Chernoff, S. B., Grote, T. H., Hahne, W. F., Kris, M. G., Navari, R. M., **Pendergrass, K. B.** Annals of Oncology, 7:136, 1996. Abstract.

"All Oral Regimens of Dolasetron and Dexamethasone to Prevent Emesis Caused by High-Dose Cisplatin." Grote, T. H., Navari, R. M., **Pendergrass, K. B.**, et al. Proceedings, American Society of Clinical Oncology, 15:537, 1996. Abstract.

"Double-blind, Randomized Study of the Dose-response Relationship Across Five Single Doses of IV Dolasetron Mesylate for Prevention of Acute Nausea and Vomiting after Cisplatin Chemotherapy." Cramer, M., DuBois, D., Hahne, W., Harman, G., Martin, L., Modiano, M., **Pendergrass, K.**, Thant, M. Proceedings, American Society of Clinical Oncology, 15:533, May 1996. Abstract.

"Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases." Blayney, D., Heffernan, M., Hortobagyi, G. N.; Knight, R. D., Lipton, A., **Pendergrass, K.**, Porter, L., Reitsma, D. J., Seaman, J., Simeone, J. F., Sinoff, C., Theriault, R. L., Wheeler, H. For The Protocol Aredia Breast Cancer Study Group (the principal investigators in the Protocol 19 Aredia Breast Cancer Study Group include Kelly B. Pendergrass, M.D.) The New England Journal of Medicine, 335:1785-1791, 1996.

"Analysis of Optimal Dose From Eight Pooled Clinical Trials Assessing the Acute Antiemetic Efficacy of IV Dolasetron Mesylate After Emetogenic Chemotherapy." Audhuy, B., Hesketh, P., **Pendergrass, K.**, et al. Proceedings, American Society of Clinical Oncology, 15: 533, 1996. Abstract.

"Oral Dolasetron (DOL) Plus Dexamethasone (DEX) Delays Time to Emesis More Effectively than IV Ondansetron (ONDAN) or IV Dolasetron Alone in High-Dose Cisplatin Treated Patients." Chernoff, S. B., Grote, T. H., Hahne, W. F., Kris, M. G., Navari, R. M., **Pendergrass, K. B.**, Memorial Sloan-Kettering Cancer Center, New York, NY; Research Medical Center, Kansas City, MO, Simon Williamson Clinic, Birmingham, AL, Salem Research Group, Winston-Salem, NC, Hoechst Marion Roussel, Inc., Kansas City, MO. Annals of Oncology, 7:136, 1996. Abstract #657P.

"All Oral Regimens of Dolasetron and Dexamethasone to Prevent Emesis Caused by High-Dose Cisplatin." Grote, T. H., Navari, R. M., **Pendergrass, K. B.**, et al. Proceedings, American Society of Clinical Oncology, 15: 537, 1996. Abstract.

"Double-Blind, Randomized Study of the Dose-Response Relationship Across Five Single Doses of IV Dolasetron Mesylate (DM) for Prevention of Acute Nausea and Vomiting (ANC) after Cisplatin Chemotherapy." Cramer, M., Dubois, D., Hahne, W., Harman, G., Martin, L., Modiano, M., **Pendergrass, K.**, Than, M. Research Medical Center, Kansas City, MO, University of Iowa Hospitals and Clinics, Iowa City, IA, Arizona Clinical Research Center, Tucson, AZ, Hoechst Marion Roussel, Kansas City, MO. Supportive Care and Bioethics/Infectious. Proceedings, American Society of Clinical Oncology, Volume 15, 1996.

"Phase II, Open-label Evaluation of Recombinant Human Macrophage Colony Stimulating Factor in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia." Ackley, L., Doukas, M., Ducher, J., Harris, J., Levine, J., **Pendergrass, K.**, Sherman, M., Smith, M., Tubridy, K., Wuschuster, M. W. Proceedings, American Society of Clinical Oncology, 1995. Abstract.

"A Randomized Phase IIB Trial Comparing High-dose Busulfan, Melphalan and Thiotepa (BuMeIT) with Carmustine, Etoposide, Cytosine Arabinoside and Cyclophosphamide (BEAC) Followed By Peripheral Blood Progenitor Cell (PBPC) Infusion in Patients with Relapsed Lymphoid Malignancies." Li, W., O'Rourke, M., **Pendergrass, K.**, Rhinehart, S., Schwartzberg, Tauer, K., Weaver, C. H. Response Oncology, 1995. Abstract.

"Randomized, Phase III Study of 5-Fluorouracil Plus High-Dose Folinic Acid vs 5-Fluorouracil Plus Folinic Acid Plus Methyl-CCNU for Patients with Advanced Colorectal Cancer." Abbruzzese, J. L., Brown, B. W., Gross, H. M., Levin, B., Levy, L. B., **Pendergrass, K. B.**, Pugh, R. P., Wade III, J. L., Winn, R. J. Cancer, 1995.

"Efficacy of Oral Ondansetron, A Selective Antagonist of 5-HT<sub>3</sub> Receptors in the Treatment of Nausea and Vomiting Associated with Cyclophosphamide-Based Chemotherapies." Burton, G., Ciociola, A., Cubeddu, L. X., Galvin, D., Meshad, M., **Pendergrass, K.**, Ryan, T., York, M., Ondansetron Study Group. American Journal of Clinical Oncology 17, No. 2:137-146, 1994.

"International Collaborative Gaucher Group Registry Program – Clinical Report No. 2." **Pendergrass, K. B.** Genzyme Corporation, 1993.

"A US Multicenter Phase II Trial of Oral Navelbine in Elderly Women with Advanced Breast Cancer." Adamkiewicz, B., Blumenreich, M., Cummings, F.,

Hohneker, J., O'Rourke, M., **Pendergrass, K.**, Robert, N., Rosenbluth, R., Schuchter, L., Vogel, C., Winer, E. Proceedings, American Society of Clinical Oncology, 1993.

"Stratified, Randomized, Double-Blind Comparison of Intravenous Ondansetron Administered as a Multiple-Dose Regimen Versus Two Single-Dose Regimens in the Prevention of Cisplatin-Induced Nausea and Vomiting." Beck, T., Bricker, L., Bryson, J., Calvin, D., Gandara, D., Hainsworth, J., Hesketh, P., House, K., Keller, A., Kish, J., Lester, E., Madajewicz, S., Mortimer, J., Murphy W., Navari, R., **Pendergrass, K.** Journal of Clinical Oncology 10, No. 12, 1992.

"A Single-Blind Comparison of Intravenous Ondansetron, a Selective Serotonin Antagonist, with Intravenous Metoclopramide in the Prevention of Nausea and Vomiting Associated with High-Dose Cisplatin Chemotherapy." Finn, A., Gandara, D., Hainsworth, J. Harker, G., Harvey, W., Hesketh, P., Kasimis, B., Khojasteh, A., Monaghan, G., Oblon, D., **Pendergrass, K.**, Siddiqui T., York, M. Journal of Clinical Oncology, 721-728, May 1991.

"Unfavorable Histologies of Non-Hodgkin's Lymphoma Treated with ProMACE-CytaBOM: A Group-wide Southwest Oncology Group Study." Dahlberg, S., Eyre, H. J., Files, J. C., Fisher, R.I., Miller, T. P., **Pendergrass, K. B.**, Weick, J. K. Journal of Clinical Oncology 8, 1951-1958, 1990.

"Ifosfamide in Clinical Practice." Bristol-Myers Monograph/Audiotape. Published 07/90 (Williamsburg, VA), 1989.

### RESEARCH

"A Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects with Non-myeloid Malignancies Receiving Multi-cycle Chemotherapy." Protocol No. 20030232. Amgen, Inc. (Principal Investigator). 2004.

"A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma." Protocol No. 3066K1-304-WW. Wyeth Research. (Principal Investigator). 2003.

"A Randomized, Double-blind, Placebo-controlled, Phase III Study in Patients with Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy with Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/ZK 222584 or Placebo." Protocol No.0135 (CONFIRM 1). Novartis Pharmaceuticals Corp. (Principal Investigator). 2003.

“A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/ZK 222584 or Placebo in Patients with Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum .” Protocol No.0133 (CONFIRM 2). Novartis Pharmaceuticals Corp. (Principal Investigator). 2003.

“A Phase II Study of MDX-010 in Patients with Stage IV Adenocarcinoma of the Breast.” Protocol No. MDX010-12. Medarex, Inc. (Principal Investigator). 2003.

“A Phase II, Randomized, Open-Label Study Evaluating the Antitumor Activity of MEDI-522, A Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin +/- Dacarbazine in Patients with Metastatic Melanoma.” Protocol No. MI-CP095. MedImmune, Inc. (Principal Investigator). 2003.

“A Phase III, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose-Titration Study of Imidapril Hydrochloride (EG006) in the Treatment of Cancer Cachexia.” Protocol No. 201. Ark Therapeutics, Ltd. (Principal Investigator). 2003.

“An Open-Label, Randomized, Multicenter Study to Evaluate the use of Zolendronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Post menopausal Women with ER+ and/or PR+ Breast Cancer, Receiving Letrozole as Adjuvant Therapy.” Protocol No. CZOL446E US32. Novartis Pharmaceuticals. (Principal Investigator) 2003.

“A Phase III, Randomized, Multicenter Study of Cetuximab, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, and Leucovorin in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma.” Protocol No. CA225014. Bristol-Myers Squibb Pharmaceutical Research Institute/ImClone Systems Inc. (Principal Investigator) 2003.

“A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy.” Protocol No. MK-0869 071-0. Merck and Co., Inc. (Principal Investigator) 2002.

"Phase II, Randomized Open-label Study of Single Agent CI-1033 in Patients with Metastatic Breast Cancer." Protocol No. 1033-011. Pfizer, Inc. (Principal Investigator). 2002,

"A Randomized, Double-Blind, Placebo-Controlled; Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and

Efficacy of MK-0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with High-Dose Cisplatin." Protocol No. MK-0869-052. Merck and Co., Inc. (Principal Investigator) 2001.

"Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination with Gemcitabine Versus Placebo in Combination with Gemcitabine in Previously Untreated Subjects with Locally Advanced (Non-resectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas." Protocol No. PC4. Apton Corporation. (Principal Investigator) 2001.

"A Multicenter, Multinational, Open-Label, Single-Arm, Phase II Study of G17DT Immunogen in Combination with Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-Based Chemotherapy." Protocol No. CC6. Apton Corporation. (Principal Investigator) 2001.

"A Multicenter, Open-Label Study to Assess the Safety and Efficacy of IV Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Repeated Chemotherapy Cycles." Protocol No. PAOL-99-06. Helsinn Healthcare, SA. (Principal Investigator) 2001.

"A Double-Blind Clinical Study to Compare Single IV Doses of Palonosetron, .025 mg. or .075 mg. and Ondansetron, 32 mg. IV, in the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting." Protocol No. PAOL-99-05. Helsinn Healthcare, SA. (Principal Investigator) 2001.

"A Double-Blind Clinical Study to Compare Single IV Doses of Palonosetron, 0.25 mg. or 0.75 mg. and Dolasetron, 100 mg. IV, in the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting." Protocol No. PAOL-99-04. Helsinn Healthcare, SA. (Principal Investigator) 2001.

"An Open Phase II Trial of the Efficacy and Safety of ISIS3521 in Patients with Low-Grade, Non-Hodgkin's Lymphoma." Protocol No. ISIS3521-CS18. ISIS Pharmaceuticals, Inc. (Principal Investigator) 2001.

"Campath-1H Compassionate Treatment in Patients with PLL Who Have Failed at Least One Prior Regimen and CII Patients Who Have Failed Fludarabine Therapy." Protocol No. CAM511-A1. L&I Partners, LP and ILEX™ Oncology, Inc. (Principal Investigator) 2000.

"A Multicenter, Phase III, Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) versus Doxorubicin and

Cyclophosphamide Followed by Docetaxel (AC→T) as Adjuvant Treatment of Operable Breast Cancer HER2Neu Negative Patients with Positive Axillary Lymph Nodes." Protocol No. BCIRG 005/ TAX GMA 301. Aventis Pharmaceuticals Inc. . (Principal Investigator) 2000.

"A Phase II, Open-Label, Prospective, Randomized, Controlled, Multicenter Study of Navelbine® (Vinorelbine Tartrate) in Combination with Gemzar® (Gemcitabine) Versus Paraplatin (Carboplatin) in Combination with Taxol® (Paclitaxel) in Chemotherapy-Naïve Subjects with Inoperable Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC): A Quality of Life (QOL) Study." Protocol No. Lil/LUN04. The Mount Sinai Comprehensive Cancer Center. (Principal Investigator) 2000.

"A Randomized, Phase III, Multicenter Trial Comparing Combination Enzyme Tablet (Wobe-Mugos®E) as Adjuvant Therapy to Standard of Care Treatment in Patients with Stages II and III Multiple Myeloma as Compared to Placebo Plus Standard of Care Treatment." Protocol No. MU-699501. MUCOS Pharma Gmb H & Co. (Principal Investigator) 2000.

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of MK-0869 for the Prevention of Acute and Delayed Chemotherapy-Induced Emesis Associated with High-Dose Cisplatin." Protocol No. 040-00. Merck & Co., Inc. (Principal Investigator) 1999.

"Phase III Randomized Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) Versus Gemcitabine HCl in Chemo-naïve Pancreatic Cancer in Patients." Protocol No. RFS 2000-02. SuperGen, Inc. (Principal Investigator) 1999.

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of MK-0869 for the Prevention of Chemotherapy-Induced Emesis Associated with Moderately Emetogenic Chemotherapy." Protocol No. 044-00. Merck & Co., Inc. (Principal Investigator) 1999.

"Phase III Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients." Protocol No. RFS 2000-09. SuperGen, Inc. (Name of protocol was originally "Phase III Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) Versus Most Appropriate Chemotherapy in Refractory Pancreatic Cancer Patients." (Principal Investigator) 1999.

"Phase III Randomized Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients that have Progressive Disease

Following Gemcitabine HCl Treatment." Protocol No. RFS 2000-06. SuperGen, Inc. (Principal Investigator) 1999.

"A Phase II Randomized Study Comparing the Safety and Efficacy of Avicine™ Administered with Gemcitabine in Patients with Pancreatic Cancer." Protocol No. AVI-138-PAN-9801. IND #BB 5907. AVI BioPharma. (Principal Investigator) 1999.

"A Phase IV, Open-Label, Multicenter, Randomized Study of Neumega® (Oprelvekin) (rh-IL11) in Patients with Lymphoma and Chemotherapy-Induced Thrombocytopenia." Protocol No. C9759-14. Millennix, Inc./Genetics Institute, Inc. (Principal Investigator) 1999.

"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Effects of Long-Term with Zoledronate (4 mg and 8 mg) When Administered Intravenously in Addition to Anticancer Therapy to Patients with Bone Metastases Secondary to Solid Tumor Cancers Other Than Breast and Prostate Cancer." Protocol No. CGP 42446 03 011 Extension. Novartis Pharmaceuticals Corporation. (Principal Investigator) 1999.

"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 mg and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients with Any Cancer with Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer." Protocol No. CGP 42446 03 011. Novartis Pharmaceuticals Corporation. (Principal Investigator) 1999.

"A Phase II Evaluation of the Optimal Schedule of SC-70935 in Patients with Breast Cancer Receiving Chemotherapy with Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)." IND #6938. G. D. Searle & Company. (Principal Investigator) 1998.

"A Randomized, Double-Blind, Multicenter, Comparative Trial of I.V. Zoledronate (4 mg or 8 mg) Versus I.V. Aredia (90 mg), as an Adjunct to Standard Therapies, in the Treatment of Multiple Myeloma and Breast Cancer Patients with Cancer-Related Bone Lesions." Protocol No. 4244603010. Novartis Pharmaceuticals. (Principal Investigator) 1998.

"A Multicenter, Multinational, Randomized Phase III Study of Docetaxel (RP56976, Taxotere®) Plus Cisplatin Versus Docetaxel (RP56976, Taxotere®) Plus Carboplatin Versus Vinorelbine Plus Cisplatin in Chemotherapy-Naïve Patients with Unresectable Locally Advanced and/or Recurrent (Stage IIIb) or Metastatic (Stage IV) Non-Small Cell Lung Cancer." Protocol RP56976-V 326. Rhone-Poulenc Rorer Research and Development. (Principal Investigator) 1998.

"A Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Vicoprofen® (hydrocodone bitartrate with ibuprofen) vs. Oxycodone HCl with Acetaminophen in Patients with Cancer Pain." Protocol No. VP-42. Knoll Pharmaceutical Company. (Principal Investigator) 1998.

"A Randomized, Double-Blind, Parallel-Group Trial to Assess Quality of Life with ARIMIDEX® and NOLVADEX™ in Combination When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women." Protocol No. 1033IE/0029:0510. Zeneca Pharmaceuticals. (Principal Investigator) 1998.

"A Randomized, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women." Protocol No. 1033ID/0029:0510. Zeneca Pharmaceuticals. (Principal Investigator) 1998.

"Phase II Study of DOXIL® in the Treatment of Patients with Refractory/Relapsed Low-Grade Non-Hodgkin's Lymphoma." Protocol No. WIRB® 970500. SEQUUS Pharmaceuticals, Inc. (Principal Investigator) 1998.

"Phase II Study of DOXIL® in the Treatment of Patients with Metastatic Breast Cancer." Protocol No. WIRB® 970499. SEQUUS Pharmaceuticals, Inc. (Principal Investigator) 1998.

"Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Combined Immunotherapy with Subcutaneous Interleukin-2 and Histamine Dihydrochloride Versus Subcutaneous Interleukin-2 Alone in Patients with Advanced Malignant Melanoma." Protocol No. MP-US-Mo1. Maxim Pharmaceuticals, Inc. 1998.

"A Double-Blind, Randomized, Active Agent (Ondansetron Plus Dexamethasone) Controlled Study to Investigate the Safety, Tolerability and Efficacy of L-758,298/L-754-030 in Cisplatin-Induced Emesis." Protocol No. 007-03. Merck Research Laboratories. (Principal Investigator) 1998.

"A Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Investigate the Safety, Tolerability and Efficacy of L-754,030 in Cisplatin-Induced Delayed Emesis." Protocol No. 007-01. Merck Research Laboratories. (Principal Investigator) 1998.

"A Randomized Phase III Trial of Carboplatin and Paclitaxel ± Etyol® (Amifostine) in Patients with Non-Small Cell Lung Cancer." Protocol No. WR-56 U.S. Bioscience, Inc. (Principal Investigator) 1998.

"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Comparative, Safety and Efficacy Study of Intravenous Zoledronate (4 and 8 mg) in Prostate Cancer Patients with Metastatic Bone Lesions Receiving Antineoplastic Therapy." Protocol No. CGP 424603039. Novartis Pharmaceuticals Corporation. (Principal Investigator) 1998.

"A Randomized Double-Blind Study of Two Doses of Zoledronate and Aredia® 90 mg in the Treatment of Tumor-Induced Hypercalcemia." Protocol No. 037. Novartis Pharmaceuticals Corporation. (Principal Investigator) 1998.

"Phase II Multicenter, Double-Blind, Randomized, Dose Ranging Study of CJ-11,974 for the Control of Cyclophosphamide and Doxorubicin Chemotherapy-Induced Emesis." Protocol No. 167-117-5053. Pfizer, Inc. (Principal Investigator) 1998.

"Phase II Multicenter, Double-Blind, Randomized, Placebo-Controlled, Multi-Regimen Study of CJ-11, 974 for the Control of High-Dose Cisplatin Chemotherapy-Induced Emesis." Protocol No. 167-116-5053. Pfizer, Inc. (Principal Investigator) 1998.

"Double-Blind, Double Dummy, Randomized, Multicenter, 2-Arm, Phase III Trial Comparing Letrozole 2.5 mg Versus Tamoxifen 20 mg as First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer." Protocol No. 2026701025. Novartis Pharmaceuticals Corporation. (Principal Investigator) 1998.

"Open-Label Study of the Effectiveness, Safety and Pharmacokinetic and Pharmacodynamic Profiles of Oral Administration of Hydromorphone Hydrochloride Controlled-Release Capsules (QD) in Patients with Moderate to Severe Cancer-Related Pain." Protocol No. HD95-0803. Purdue Pharma L.P. (Principal Investigator) 1998.

"An Evaluation of a Single Oral Dose of Dolasetron Mesylate Plus Dexamethasone for Prevention of Acute Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy." Protocol No. M073147/4116. Hoechst Marion Rouse, Inc. (Principal Investigator) 1998.

"Efficacy and Tolerability of 2.5 mg Itasetron with 20 mg Dexamethasone Intravenously and of 32 mg Ondansetron with 20 mg Dexamethasone Intravenously in the Prevention of Vomiting and Nausea in Patients Undergoing Cisplatin ( $\geq 75$  mg/m<sup>2</sup>) Containing Chemotherapy." Protocol No. 208.608. Boehringer Ingelheim KG. (Principal Investigator) 1998.

"Double-Blind, Randomized, Two-Period, Crossover Study Comparing the Efficacy, Safety and Pharmacokinetic and Pharmacodynamic Profiles of Oral Administration of

Hydromorphone Hydrochloride Immediate-Release Tablets (QID) for Cancer-Related Pain." Protocol No. HD95-0802. Purdue Pharma L.P. (Study approved 07/97; begun 02/98). (Principal Investigator) 1998.

"A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination with Doxorubicin and Cyclophosphamide (FAC) as First-Line Chemotherapy for Metastatic Breast Cancer." Protocol No. RP 56979-V-307. Rhone-Poulenc Rorer Research and Development. (Principal Investigator) 1998.

"Treatment Use Protocol for Raltitrexed in Subjects with Colorectal Cancer Who are Either 5-Fluorouracil (5-FU) Intolerant or Dihydropyrimidine Dehydrogenase (DPD)-Deficient or Who Have Failed Prior Therapy." Protocol No. 1694IL0021:0022." Zeneca Pharmaceuticals. (Amended protocol). (Principal Investigator) 1998.

"A Double-Blind, Randomized, Active Agent (Ondansetron Plus Dexamethasone) Controlled Study to Investigate the Safety, Tolerability and Efficacy of L-758,298/L754,030 in Cisplatin-Induced Emesis." Protocol No. 007-03. Merck Research Laboratories. (Principal Investigator) 1998.

"A Randomized Double-Blind Study of Two Doses of Zoledronate and Aredia® 90 mg in the Treatment of Tumor-Induced Hypercalcemia." Protocol No. 037. Novartis Pharmaceuticals Corporation. (Principal Investigator) 1997.

"A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Anastrozole (Arimidex™) 1 mg Daily) with Tamoxifen Citrate (20 mg Daily) as First-Line therapy for Advanced Breast Cancer in Postmenopausal Women." Protocol No. 1033IL/0030:0114. Protocol Version 03. (Principal Investigator) 1997.

"A Comparative Trial of Weekly Intravenous Onconase® + Daily Oral Tamoxifen Versus Intravenous Gemzar® Weekly in Patients with Advanced Pancreatic Cancer." Protocol No. P30-303. Alfacell Corporation. (Principal Investigator) 1997.

"A Comparative Trial of Intravenous Onconase® + Daily Tamoxifen Versus Intravenous 5-Fluorouracil Weekly in Patients with Advanced Pancreatic Cancer." Protocol No. P30-303. Alfacell Corporation. (Principal Investigator) 1997.

"A Randomized, Double-Blind Trial Comparing Arimidex Alone with Nolvadex Alone with Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Postmenopausal Women with Breast Cancer." Protocol No. 1033IL/0029:0510. Zeneca Pharmaceuticals Group. (Principal Investigator) 1997.

"A Multicenter Study Evaluating the Safety and Efficacy of Technetium Tc-99m P829 for the Detection and Localization of Non-Small Cell Lung Cancer." Protocol No. 829-34. Diatide, Inc. (Principal Investigator) 1997.

"An Open-Label, Non-Comparative, Multicenter Phase II Study of Oral Topotecan as a Single Agent, Second Line Therapy Administered for Five Days in Patients with Advanced Ovarian Cancer." Protocol No. 151. SmithKline Beecham Pharmaceuticals. (Principal Investigator) 1997.

"A Double-Blind, Randomized, Parallel-Group Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of L-754,030 in Cisplatin-Induced Delayed Emesis." Protocol No. 007. Merck & Co., Inc. (Principal Investigator) 1997.

"A Two-Stage Phase II Safety and Efficacy Study of IntraDose™ (Cisplatin/Epinephrine) Injectable Gel (MPI5010) Administered to Patients with Unresectable Unresectable Intrahepatic Colorectal Metastases." Protocol No. MP405-96-2. Matrix Pharmaceutical. (Principal Investigator) 1997.

"A Two-Stage Phase II Safety and Efficacy Study of IntraDose™ (Cisplatin/Epinephrine) Injectable Gel (MPI5010) Administered to Patients with Unresectable Primary Hepatocellular Carcinoma." Protocol No. MP417-96-2. Matrix Pharmaceutical. (Principal Investigator) 1997.

"Treatment Use Protocol for Raltitrexed In Subjects with Metastatic or Recurrent Colorectal Carcinoma Who Are Either 5-Fluorouracil (5-FU) Intolerant or Dihydropyrimidine Dehydrogenase (DPD)-Deficient." Protocol No. 1694IL/0021. Zeneca Pharmaceuticals. (See amendment to protocol 1998). (Principal Investigator) 1997.

"Efficacy and Tolerability of Oral Itasetron 1 mg b.i.d. and 2.5 mg b.i.d. Compared with Oral Ondansetron 8 mg b.i.d. Over Three Consecutive Days in the Prophylactic Treatment of Vomiting and Nausea in Patients Undergoing Moderately Emetogenic Chemotherapy." Protocol No. 208.609. Boehringer Ingelheim KG. (Principal Investigator) 1997.

"A Multicenter, Randomized, Phase III of Docetaxel 100 mg/m<sup>2</sup> Versus Docetaxel 75 mg/m<sup>2</sup> vs Docetaxel 60 mg/m<sup>2</sup> as Second-Line Chemotherapy for Patients with Advanced Breast Cancer." Protocol No. RP 56976-TAX313/IND No. 35,555. Rhone-Poulenc Rorer Pharmaceuticals, Inc. (Principal Investigator) 1996.

"A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Anastrozole (Arimidex® 1 mg daily) with Tamoxifen Citrate (20 mg daily) as First-

Line Therapy for Advanced Breast Cancer in Postmenopausal Women." Protocol No. 1033IL/0030:0114. Zeneca Pharmaceuticals. (Principal Investigator) 1996.

"Efficacy and Tolerability of 2.5 mg Itasetron Intravenously and of 32 mg Ondansetron Intravenously in the Prevention of Vomiting and Nausea in Patients Undergoing Cisplatin ( $\geq 75$  mg/m<sup>2</sup>) Containing Chemotherapy." Protocol No. 208.608. Boehringer Ingelheim KG. (Principal Investigator) 1996.

"Multicenter, Open-Label, Randomized, 2-Arm, Phase II Trial of Letrozole (2.5 mg p.o. q.d.) Versus the Combination of Letrozole (2.5 mg p.o. q.d.) + Tamoxifen (20.0 mg p.o.q.d.) As First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer." Protocol No. 01026/Version 3 (May 1996). CIBA-Geigy Corporation. (Principal Investigator) 1996.

"An Open Protocol for the Use of Agrelin® (Anagrelide) for Patients with Thrombocytopenia." Protocol 13,970-301B. Roberts Pharmaceutical Corporation. (Principal Investigator) 1996.

"A Randomized, Double-Blind Comparison of Oral Mesylate Plus Dexamethasone to Intravenous Ondansetron Plus Dexamethasone in Patients Receiving High-Dose Cisplatin." Protocol No. MCPR01/08/Study No. MCST0476. Hoechst Marion Roussel, Inc. (Principal Investigator) 1996.

"An Evaluation of Oral Regimens of Dolasetron Mesylate and Dexamethasone for Prevention of Delayed Nausea and Vomiting Following Cisplatin Chemotherapy." Protocol No. MCPR0106/Study No. MCST0454. Hoechst Marion Roussel. (Principal Investigator) 1995.

"Comparison of Two Doses (0.5 mg and 2.5 mg) of Letrozole (CGS 20267) Versus Megestrol Acetate in Postmenopausal Women with Advanced Breast Cancer." Protocol No. 02. CIBA-Geigy Corporation. (Principal Investigator) 1995.

"A Prospectively Randomized, Multicenter Trial Comparing the Effects of a Novel Peptide-Based Enteral Formula Versus a Regular Diet on the Extent of Gastrointestinal Toxicities Associated with 5-Fluorouracil Plus Low-Dose Leucovorin Chemotherapy in Colorectal Cancer Patients." Protocol No. BG68. Ross Products Division/Abbot Laboratories. (Principal Investigator) 1995.

"An Oral Regimen of Dolasetron and Dexamethasone for Prevention of Emesis Following Cisplatin Chemotherapy." Protocol No. MCPR0103. Marion Merrell Dow, Inc. (Principal Investigator) 1995.

"An Evaluation of Dose Regimens of Dolasetron and Dexamethasone for Prevention

of Emesis Following Cisplatin." Protocol No. MCPR0104. Marion Merrell Dow, Inc. (Principal Investigator) 1995.

"An Open Label, Long-Term, Multicenter Study of Oral Transmucosal Fentanyl Citrate (OTFC) for the Treatment of Breakthrough or Incident Pain in Cancer Patients Previously Enrolled in Other OTFC Studies." Protocol No. AC200/014. Anesta Corp. (Principal Investigator) 1995.

"A Multicenter, Double-Blind, Placebo Controlled Crossover Study of Oral Transmucosal Fentanyl Citrate (OTFC) for the Treatment of Breakthrough Pain in Cancer Patients Taking Stable Doses of Oral Opioids." Protocol No. AC 200/013. Anesta Corp. (Principal Investigator) 1995.

"A Phase III, Two-Armed, Multicenter, Randomized, Controlled Comparison of the Efficacy of Cisplatin Alone Versus Cisplatin and Tirapazamine in Subjects with Advanced (Stage IIIB and IV), Previously Untreated Non-Small Cell Lung Tumors (CATAPULT)." Protocol No. 59075-205. Sanofi-Winthrop, Inc. 1995.

"A Phase III Randomized Trial of Losoxantrone + Paclitaxel Versus Paclitaxel Alone in Patients with Stage IV Breast Cancer." Protocol No. DuP 941-017. DuPont Merck Pharmaceutical Company. (Principal Investigator) 1995.

"A Phase II-III Clinical Trial of Onapristone in Patients with Advanced Breast Cancer." Protocol N. BL07-3113. Berlex Laboratories. (Principal Investigator) 1995.

"A Double-Blind, Multicenter, Parallel Study Comparing the efficacy and Safety of Oral Granisetron Hydrochloride 2 mg with Intravenous Ondansetron Hydrochloride 32 mg. Given Once Prior to Chemotherapy in the Prevention of Nausea and Vomiting Induced by Cisplatin-Based Chemotherapy." Protocol No. BRL43694/341. SmithKline Beecham Pharmaceuticals. (Principal Investigator) 1995.

"Efficacy and Safety Trial of Toremifene Versus Tamoxifen in Postmenopausal Patients with Metastatic Breast Cancer." Protocol No. 092011. Orion-Farmos, Inc. (Principal Investigator) 1995.

"An Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Intravenous Kytril™ (Granisetron Hydrochloride) in the Prevention of Chemotherapy-Induced Nausea and Vomiting." Protocol No. BRL 4364A/345. SmithKline Beecham Pharmaceuticals. (Principal Investigator) 1994.

"A Dose Ranging, Efficacy, Safety, and Pharmacokinetic Study of Single Oral Doses of RS-25259 for Prevention of Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients Receiving Highly Emetogenic Chemotherapy." Protocol No. 2332. Syntex

Development Research/Division of Syntex, Inc. (Principal Investigator) 1993.

"A Dose Ranging, Efficacy, Safety and Pharmacokinetic Study of Single Intravenous Doses of RS-25259 for Prevention of Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients Receiving Highly Emetogenic Chemotherapy." Protocol No. 2330. Syntex Development Research/Division of Syntex, Inc. (Principal Investigator) 1993.

"5-Fluorouracil, Adriamycin, Cytosar Versus 5-Fluorouracil, Adriamycin, Cytosar + ADR-529 in the Treatment of Disseminated Carcinoma of the Breast with Endomyocardial Biopsy Study to Evaluate the Efficacy of ADR-529 (NSC 169870, ICRF-187)." Adria Laboratories. (Principal Investigator) 1992.

"A Five-Arm, Double-Blind, Randomized Dose-Response Study of the Antiemetic Effectiveness of IV Dolasetron Mesylate in Patients Receiving Cisplatin Chemotherapy." Marion Merrell Dow. (Principal Investigator) 1992.

"A Clinical Trial of Oral Navelbine for First and Second Line Treatment of Women 65 Years of Age or Older with Advanced Breast Cancer." Burroughs-Wellcome (PAREXEL). (Principal Investigator) 1992.

"Comparative Trial of Aredia Versus Placebo for the Prevention of Skeletal-Related Complications in Patients with Breast Cancer and Lytic Bone Lesions Treated with Hormonal Therapy." CIBA-Geigy Corporation. (Principal Investigator) 1992.

"Multicenter, Randomized, Blind dose Response Study of Three Doses of Oral RG-12915 Versus IV Ondansetron for the Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving High-Dose Cisplatin Chemotherapy for the First Time." Rorer. (Principal Investigator) 1992.

"Intron A (Alpha-Interferon) in the Treatment of Multiple Myeloma." Protocol SCHPL9001. Schering. (Principal Investigator) 1991.

"A Double-Blind, Randomized, Placebo Controlled, Multicenter Study of Diethyldithiocarbamate (DDTC) Used as a Protective Agent Against Cisplatin Induced Toxicities in Patients with Small Cell Lung Cancer or Non-Small Cell Lung Cancer." MGI PHARMA, Inc. (Principal Investigator) 1991.

"A Randomized, Double-Blind Placebo Controlled Trial of Oral Ondansetron in the Prevention of Nausea and Vomiting Post Cisplatin Chemotherapy, Phase III." Glaxo, Inc. (Principal Investigator) 1988.

"Randomized, Double-Blind Trial of Ondansetron vs Metoclopramide for Intermediate Dose Cisplatin, Phase III." Glaxo, Inc. (Principal Investigator) 1988.

"Randomized Trial of Ondansetron vs Metoclopramide for High-Dose Cisplatin Induced Nausea/Vomiting, Phase III." Glaxo, Inc. (Principal Investigator) 1988.

"Piritrexime in Metastatic Malignant Melanoma, Phase III." Burroughs-Wellcome Co. (Principal Investigator) 1988.

"Toremifene vs Tamoxifen in Carcinoma of the Breast, Phase III." Adria Laboratories (study re-titled currently – see below – effective 1995 – company is now Orion-Farmos, Inc.) (Principal Investigator) 1988.

"ADR-529 ± Adriamycin in Carcinoma of the Breast, Phase III." Adria Laboratories. (Principal Investigator) 1988.

"ADR-529 ± Adriamycin in Small Cell Lung Carcinoma, Phase III." Adria Laboratories. (Principal Investigator) 1988.

"Epirubicin vs Adriamycin in Ovarian Carcinoma, Phase III." Adria Laboratories. (Principal Investigator) 1988.

"Epirubicin vs Adriamycin in Gastric Carcinoma, Phase III." Adria Laboratories. (Principal Investigator) 1986.

"Epirubicin vs Adriamycin in Small Cell Lung Carcinoma, Phase III." Adria Laboratories. (Principal Investigator) 1986.

"Aziocillin for Sepsis in the Neutropenic Cancer Patient." Miles Laboratories. (Principal Investigator) 1985.

"Butorphanol for Chemotherapy Induced Nausea/Vomiting, Phase I-II." Study Bristol Myers Co. (Principal Investigator) 1984.

Clinical Protocols. The Southwest Oncology Group (KCCOP) 1980-Present

"Oat Cell Carcinoma." Johns Hopkins Oncology Center 1979.

"3 Deazuridine." Johns Hopkins Oncology Center 1978.

"High-Dose Methotrexate – 5FU with Citrovorum Factor Rescue." Brown University 1978.

"Xeroderma Pigmentosa." Kansas University Medical Center 1975.

"Shock Lung." Kansas University Medical Center,

Surgical Research Scholarship/Grant. 1975.

"Effects of Quabain of Na<sup>+</sup>/K<sup>+</sup> Pump in Rabbit Myocardium." Kansas University Medical Center, Department of Physiology, Kaw Valley Heart Association Scholarship. 1970.

## PROFESSIONAL MEMBERSHIPS

American College of Physicians  
American Medical Association  
American Society of Clinical Oncology  
American Society of Internal Medicine  
Jackson County Medical Association  
Johns Hopkins Medical and Surgical Alumni  
Kansas City Round Table of Oncology  
Missouri Society of Internal Medicine  
Missouri State Medical Association  
Sigma Alpha Epsilon Fraternity  
Southwest Clinical Society  
The University of Kansas School of Medicine Alumni Association  
The University of the South Alumni Association

